Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.862 SEK | +0.98% | -9.39% | +5.08% |
Apr. 29 | Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024 | |
Apr. 29 | Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina | CI |
Sales 2021 | 844K 78.04K | Sales 2022 | 1.14M 106K | Capitalization | 595M 55.04M |
---|---|---|---|---|---|
Net income 2021 | -156M -14.42M | Net income 2022 | -168M -15.53M | EV / Sales 2021 | 1,710 x |
Net cash position 2021 | 254M 23.5M | Net cash position 2022 | 68.47M 6.33M | EV / Sales 2022 | 460 x |
P/E ratio 2021 |
-10.9
x | P/E ratio 2022 |
-3.54
x | Employees | 11 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 75.52% |
Latest transcript on Immunovia AB
1 day | +0.98% | ||
1 week | -9.39% | ||
Current month | -8.28% | ||
1 month | +33.19% | ||
3 months | +5.32% | ||
6 months | +227.82% | ||
Current year | +5.08% |
Managers | Title | Age | Since |
---|---|---|---|
Jeff Borcherding
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | 62 | 22-03-31 | |
Karl Stone
COO | Chief Operating Officer | 61 | 23-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 16-12-08 | |
Peter Andersen
CHM | Chairman | 67 | 19-12-31 |
Michael Löfman
BRD | Director/Board Member | - | 23-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 1.862 | +0.98% | 349,058 |
24-05-02 | 1.844 | -9.16% | 1,843,115 |
24-04-30 | 2.03 | -6.24% | 287,814 |
24-04-29 | 2.165 | +5.35% | 760,613 |
24-04-26 | 2.055 | +2.75% | 1,008,622 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 11:29 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+5.08% | 7.81M | |
-42.33% | 2.84B | |
+17.00% | 1.85B | |
-0.51% | 1.66B | |
+27.15% | 1.26B | |
-13.90% | 989M | |
-21.76% | 896M | |
-2.72% | 757M | |
-23.95% | 637M | |
+6.84% | 500M |
- Stock Market
- Equities
- IMMNOV Stock